NasdaqGS:INDVPharmaceuticals
Indivior (INDV) Is Up 22.8% After Strong Q2 Beat and Full-Year Revenue Outlook Raised Has the Bull Case Changed?
Indivior PLC recently reported strong second quarter 2025 earnings, swinging to a US$18 million net income and surpassing analyst expectations for both sales and earnings, prompting management to raise full-year revenue guidance to a range of US$1.03 billion to US$1.08 billion.
The company’s results were fueled by robust performance from its flagship addiction treatment products and supported by positive real-world clinical data demonstrating meaningful health outcomes for opioid use...